MedTrace Logo

Benefits of Amantadine in Patients With Coma State

NCT03443037 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2018-09-06

No results posted yet for this study

Summary

The study was a single center observational-prospective study and approved by local ethics committee. Patients in coma state due to traumatic brain injury, cardiac arrest or ischemic stroke who are older than 18 years of age were included in the study. Patients who received amantadine 200mg/day for fourteen days according to ICU protocols decided by primary physician formed the amantadine group, and the rest of the subjects were included in the control group. All patients were evaluated for Glasgow Coma Score, JFK Coma Recovery Scale and Disability Rating Scale once a week for three months.

Conditions

  • Coma; Prolonged
  • Amantadine

Interventions

DRUG

amantadine sulphate

Sponsors & Collaborators

  • Dokuz Eylul University

    lead OTHER

Principal Investigators

  • Necati Gokmen, MD · Dokuz Eylul University

  • Kutlay Aydin · Dokuz Eylul University

  • Kutlay Aydin · Dokuz Eylul University

  • Begum Ergan · Dokuz Eylul University

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-01
Primary Completion
2019-07-01
Completion
2019-07-01
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03443037 on ClinicalTrials.gov